Target Name: ZNF467
NCBI ID: G168544
Review Report on ZNF467 Target / Biomarker Content of Review Report on ZNF467 Target / Biomarker
ZNF467
Other Name(s): zinc finger protein 467 | Zinc finger protein EZI | Zfp467 | zinc finger protein EZI | ZN467_HUMAN | ZNF467 variant 1 | EZI | Zinc finger protein 467 (isoform 1) | Zinc finger protein 467, transcript variant 1 | Zinc finger protein 467

ZNF467: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder that affects movement and cognition. It is characterized by the progressive loss of brain cells, leading to motor symptoms such as tremors, rigidity, and difficulty with movement. While there is currently no cure for Parkinson's disease, drug treatments can help manage symptoms and improve quality of life. ZNF467, a gene that has been identified as a potential drug target and biomarker for Parkinson's disease, is a promising candidate for further research.

The ZNF467 gene is located on chromosome 12q34 and encodes for a protein known as ZNF467. ZNF467 plays a role in the development and maintenance of neural stem cells, which are critical for the growth and function of the brain. It is also involved in the regulation of the immune response and has been implicated in the development of neuroinflammation.

In previous studies, researchers have shown that ZNF467 is expressed in the brains of individuals with Parkinson's disease and that its levels are decreased in the brains of individuals with the disease. This suggests that ZNF467 may be a potential drug target for Parkinson's disease.

One of the key challenges in developing a new drug for Parkinson's disease is identifying the underlying cause of the disease and determining the best way to target the affected protein. ZNF467 is a good candidate for drug targeting because it is involved in multiple cellular processes that are relevant to the development and progression of Parkinson's disease.

In addition to its role in neural stem cells, ZNF467 is also involved in the regulation of the immune response. Studies have shown that ZNF467 is involved in the regulation of T cell activity, which is important for the immune response. This suggests that ZNF467 may be a potential drug target for diseases that are characterized by inflammation, such as Parkinson's disease.

Another potential drug target for ZNF467 is its role in the regulation of cell growth. Studies have shown that ZNF467 is involved in the regulation of cell growth and that this function may be important for the development and progression of cancer. This suggests that ZNF467 may be a potential biomarker for cancer, as well as a potential drug target for cancer.

In conclusion, ZNF467 is a promising candidate for drug targeting and biomarker for Parkinson's disease. Further research is needed to determine the best way to target the affected protein and to develop new treatments for Parkinson's disease. By identifying the underlying causes of the disease and developing new treatments, we can improve the quality of life for individuals with Parkinson's disease.

Protein Name: Zinc Finger Protein 467

Functions: Transcription factor that promotes adipocyte differentiation and suppresses osteoblast differentiation in the bone marrow. Enhances the osteoclast-supporting ability of stromal cells. Binds with STAT3 the consensus sequence 5'-CTTCTGGGAAGA-3' of the acute phase response element (APRE). Transactivates several promoters including FOS, OSM and PPARG. Recruits a histone deacetylase complex (By similarity)

The "ZNF467 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF467 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF468 | ZNF469 | ZNF470 | ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488 | ZNF490 | ZNF491 | ZNF492 | ZNF493 | ZNF496 | ZNF497 | ZNF497-AS1 | ZNF500 | ZNF501 | ZNF502 | ZNF503 | ZNF503-AS1 | ZNF503-AS2 | ZNF506 | ZNF507 | ZNF510 | ZNF511 | ZNF512 | ZNF512B | ZNF513 | ZNF514 | ZNF516 | ZNF516-DT | ZNF517 | ZNF518A | ZNF518B | ZNF519 | ZNF519P3 | ZNF521 | ZNF524 | ZNF525 | ZNF526 | ZNF527 | ZNF528 | ZNF528-AS1 | ZNF529 | ZNF529-AS1 | ZNF530 | ZNF532 | ZNF534 | ZNF536 | ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547 | ZNF548 | ZNF549 | ZNF550 | ZNF551 | ZNF552 | ZNF554 | ZNF555 | ZNF556 | ZNF557 | ZNF558 | ZNF559 | ZNF559-ZNF177 | ZNF560 | ZNF561 | ZNF561-AS1 | ZNF562 | ZNF563 | ZNF564 | ZNF565 | ZNF566 | ZNF566-AS1 | ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579